KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CRISPR Therapeutics AG (CRSP) Equity Ratio (2016 - 2025)

CRISPR Therapeutics AG's Equity Ratio history spans 11 years, with the latest figure at 0.85 for Q4 2025.

  • For Q4 2025, Equity Ratio fell 1.55% year-over-year to 0.85; the TTM value through Dec 2025 reached 0.85, down 1.55%, while the annual FY2025 figure was 0.85, 1.55% down from the prior year.
  • Equity Ratio for Q4 2025 was 0.85 at CRISPR Therapeutics AG, down from 0.85 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.92 in Q1 2021 and bottomed at 0.83 in Q1 2023.
  • The 5-year median for Equity Ratio is 0.85 (2022), against an average of 0.85.
  • The largest annual shift saw Equity Ratio increased 4.83% in 2021 before it dropped 6.77% in 2022.
  • A 5-year view of Equity Ratio shows it stood at 0.87 in 2021, then decreased by 4.11% to 0.84 in 2022, then grew by 1.0% to 0.84 in 2023, then grew by 2.05% to 0.86 in 2024, then decreased by 1.55% to 0.85 in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Equity Ratio are 0.85 (Q4 2025), 0.85 (Q3 2025), and 0.84 (Q2 2025).